Abstract
Ovarian carcinoma is a moderately chemosensitive tumour and since most patients present with advanced disease, attention continues to be focused on new systematic treatment initiatives. Comparisons between clinical trial outcomes in ovarian carcinoma have in the past been made difficult as a result of differences between populations studied, variations in sample size which has affected the statistical power to compare two or more treatment arms, and inattention or inability to account for variations in drug doses between studies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Levin, L. and Hryniuk, W.M. (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol. 5, 756–67.
Ozols, R.F., Corden, B.J., Jacob, J. et al. (1984) High dose cisplatinum in hypertonic saline. Ann. Intern. Med 100,19–24.
Ngan, H.Y.S., Choc, Y.C., Cheung, M. et al (1989) A randomized study of high dose vs low-dose cisplatinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35, 221–7.
Kaye, S.B., Lewis, C.R., Paul, J. et al (1992) Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340,329–33.
McGuire, W.P., Hoskins, W.J., Brady, M.F. et al (1992) A phase III trial of dose intense (DI) vs standard dose (DS) cisplatin (CDDP) and Cytoxan (CTX) in advanced ovarian cancer (AOC). Proc. Am. Sac. Clin. Oncol 11, A718.
Boni, C., Cocconi, G., Lottici, R. et al (1990) Conventional vs high dose intensity cisplatin in advanced ovarian cancer. Preliminary report of a randomized trial. Proc. Am. Soc. Clin. Oncol 9 A651.
Colombo, N., Pittelli, M.R., Marzola, M. et al (1990) Randomized study of two cisplatin (P) dose intensity regimens in patients with stage III/IV epithelial ovarian cancer (HOC). Proc. Am. Soc. Clin. Oncol 9 A619.
Jacobs, A.J., Sommers, G.M., Homan, S.M. et al (1988) Therapy of ovarian carcinoma: the relationship of dose level and treatment intensity to survival. Gynecol Oncol 31, 233–45.
Levin, L. (1993) Dose intensity in the treatment of ovarian carcinoma. In Cancer of the Ovary (eds M. Markman and W.J. Hoskins), Raven Press, New York, pp. 251–60.
Hunter, R.W., Alexander, N.D.E. and Soutter, W.P. (1992) Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am. J. Obstet. Gynecol 166, 504–11.
Levin, L., Simon, R. and Hryniuk, W.M. (1993) The importance of multiagent chemotherapy regimens in ovarian carcinoma - dose intensity analysis, J. Natl Cancer Inst 85,1732–42.
Ovarian Cancer Meta-Analysis Project (1991) Cyclophosphamide plus cisplatin vs cyclophosphamide, doxorubicin, and cisplatin chemotherapy in ovarian carcinoma: a metaanalysis. J. Clin. Oncol 9 1668–74.
Kankipati, S.R. and Wiltshaw, E. (1981) A prospective randomized study of cisplatinum as a single agent and in combination with chlorambucil in advanced ovarian carcinoma. Br. J. Cancer. 44, 289.
Tomirotti, M., Perrone, S., Gie, P. et al (1988) Cisplatin (P) vs cyclophosphamide, adri- amycin and cisplatin (CAP) for stage III/IV epithelial ovarian carcinoma: a prospective randomized trial. Turnori 74, 573–7.
Wiltshaw, E., Evans, B., Rustin, G. et al (1986) A prospective randomized trial comparing 17. high dose cisplatin with low dose cisplatin and chlorambucil in advanced ovarian carcinoma. J. Clin. Oncol 4, 722–9.
Gruppo Interegionale Cooperativo Oncologico Ginecologia (1987) Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/ cisplatin in advanced ovarian cancer. Lancet ii, 353–9.
Bruckner, H.W., Cohen, C.J., Goldberg, J.D. et al (1981) Improved chemotherapy for ovarian cancer with cis-diammine dichloro- platinum and adriamycin. Cancer 47, 2288–94.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Chapman & Hall
About this chapter
Cite this chapter
Levin, L. (1995). Chemotherapy options in ovarian carcinoma — a dose intensity perspective. In: Sharp, F., Mason, P., Blackett, T., Berek, J. (eds) Ovarian Cancer 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0136-4_20
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0136-4_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0138-8
Online ISBN: 978-1-4757-0136-4
eBook Packages: Springer Book Archive